Visco Tablet

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Visco Tablet

What is Visco Tablet?

Visco Tablet is a pharmaceutical formulation primarily utilized for the management of symptoms associated with venous insufficiency and hemorrhoidal disease. It belongs to a class of medications known as phlebotonics or vasoprotective agents, which are designed to influence the tone of the blood vessels.

Composition and Mechanism

The active ingredients in Visco Tablet typically consist of purified flavonoid fractions, most commonly diosmin and hesperidin. These compounds are naturally occurring substances found in certain plants, particularly citrus fruits.

The medication works by acting on the vascular system in several ways:

  • Venous Tone: It helps increase the tension in the walls of the veins, which may improve blood flow and reduce the pooling of blood in the lower extremities.
  • Microcirculation: It assists in protecting the smaller blood vessels (capillaries) by increasing their resistance and reducing their permeability, which can help minimize fluid leakage into surrounding tissues.
  • Lymphatic Drainage: It may enhance lymphatic flow, aiding in the removal of excess fluid from the interstitial spaces.

Therapeutic Intent

The primary goal of using Visco Tablet is to address the underlying physiological issues related to poor venous circulation. By improving vascular resistance and reducing venous distensibility, the medication aims to alleviate common clinical manifestations such as:

  • A feeling of heaviness or aching in the legs.
  • Localized swelling (edema) in the lower limbs.
  • Discomfort associated with acute or chronic hemorrhoidal episodes.

While Visco Tablet helps manage these symptoms, it is often used as part of a broader approach to vascular health that may include lifestyle modifications.

Regulatory References

  1. Alginates for GERD
  2. MedlinePlus Antacids

What side effects are possible with Visco Tablet?

Possible Side Effects and Safety Information: Visco Tablet

The official safety profile for Visco Tablet (Sodium Hyaluronate viscosupplement) is primarily characterized by localized adverse reactions at the injection site, as classified by government regulatory authorities.


Frequency of Adverse Reactions

The most frequent adverse events are classified in regulatory documents as common. These are typically transient and limited to the injected joint and administration area. Rare but serious reactions are also documented.

Classification Example Reactions (System-Organ Class)
Common Joint pain (arthralgia), joint swelling, joint effusion (fluid accumulation), joint stiffness, and localized redness or warmth.
Rare Systemic hypersensitivity reactions, including anaphylactic or anaphylactoid events.

Serious Adverse Reactions and Safety Constraints

While most effects are localized, the potential for systemic hypersensitivity reactions exists and is documented as a rare but serious adverse event. A severe, acute inflammatory reaction in the knee has also been noted.

Safety constraints dictate that the medicine is contraindicated in patients with a known hypersensitivity to sodium hyaluronate preparations. It must also not be injected into the knee joint if there are infections or skin diseases in the area of the injection site, or if the joint is severely inflamed. Safety has not been established for use in pregnant or lactating women or in pediatric patients, as defined in regulatory labeling.

Overdose and Emergency Response

Overdose and when to seek help

Overdose with Visco Tablet, a combination antacid product, is primarily associated with the effects of excessive mineral salt ingestion, as documented in official regulatory labeling. Documented manifestations commonly include severe gastrointestinal presentations such as persistent diarrhea or constipation, nausea, vomiting, and abdominal pain. Physiologically, overdose may lead to significant metabolic derangement, presenting as Hypermagnesemia (elevated serum magnesium) and Hypophosphatemia (low serum phosphate).


Severity and Emergency Response

Life-threatening systemic complications, including acute renal failure and profound metabolic alkalosis, may occur in cases of severe or prolonged over-ingestion. Patients with pre-existing renal impairment are at a documented, elevated risk for severe Hypermagnesemia, which necessitates heightened consideration during management.

The official regulatory guidance mandates that patients must seek immediate medical attention following any suspected overdose. Treatment procedures are strictly symptomatic and supportive, focused on the correction of severe fluid and electrolyte imbalances; no specific antidote is known for this combination. Hospital monitoring may be required to observe the patient's condition and continuously track serum electrolytes and renal function. The need to contact emergency services is explicitly stated for any sign of severe or rapidly escalating systemic symptoms.

Therapeutic Uses of Visco Tablet

Main Uses of Visco Tablet

Visco Tablet is primarily utilized for the management of symptoms associated with various musculoskeletal conditions. It is commonly indicated for individuals experiencing pain and inflammation related to joint and muscle disorders.

Osteoarthritis and Rheumatoid Arthritis

The medication is frequently used to alleviate the persistent joint pain, stiffness, and swelling characteristic of osteoarthritis and rheumatoid arthritis. By addressing the underlying inflammatory processes, it helps improve joint mobility and comfort for patients with these chronic conditions.

Acute Musculoskeletal Pain

Visco Tablet is also effective in treating acute episodes of pain resulting from muscle strains, sprains, or other soft tissue injuries. It assists in reducing localized inflammation and discomfort following physical trauma or overexertion.

Other Inflammatory Conditions

In addition to joint-specific ailments, the tablet may be used to manage pain and inflammation associated with conditions such as ankylosing spondylitis and various forms of tendonitis or bursitis.

Benefits of Treatment

Reduction of Inflammation

One of the primary benefits of Visco Tablet is its ability to inhibit the production of chemicals in the body that cause inflammation. This reduction in swelling and redness is essential for the healing process and for preventing further tissue damage.

Pain Management

By targeting inflammatory pathways, the medication provides significant relief from both chronic and acute pain. This allows patients to engage more effectively in daily activities and physical therapy.

Improved Physical Function

As pain and inflammation subside, many patients experience a restoration of function in the affected areas. This improvement in flexibility and strength contributes to a better overall quality of life and increased independence in movement.

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Visco Tablet

Visco Tablet (Sodium Hyaluronate viscosupplement) is officially indicated for adult patients with osteoarthritis of the knee whose pain was not adequately relieved by conservative non-drug treatments or simple pain relievers. The regulatory profile strictly defines who is eligible and who must not use the medicine.


Populations Restricted from Use

The medicine is contraindicated (must not be used) in patients with a known allergy or hypersensitivity to sodium hyaluronate. It is also prohibited for use in patients who have infections or skin diseases at the intended injection site or within the affected knee joint.


Unestablished Safety Populations

Safety and effectiveness have not been established in pediatric patients (under 18 years of age), pregnant women, or lactating women. Therefore, use is generally not recommended in these populations.

Conditional use is required in patients with conditions like venous or lymphatic stasis in the treatment leg or a history of avian protein allergies, depending on the formulation’s source material.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section summarizes the clinically significant interaction information for Visco Tablet as documented in official government regulatory labeling.


Pharmacokinetic Interaction (Absorption)

Visco Tablet is officially documented to interfere with the systemic absorption of many co-administered medicinal products. This interaction is classified as clinically significant because it may reduce the effectiveness of other essential medicines. The regulatory documents explicitly state that the tablet's components can make it harder for the body to absorb other medicines.

Interaction-Related Constraint

To manage the absorption interference, official labeling mandates a strict temporal separation requirement. Patients are instructed to avoid taking any other medicine within 2 hours before or 2 hours after taking Visco Tablet. This procedural constraint is necessary to minimize the risk of therapeutic failure for the co-administered medication.

Drug Class of Special Consideration

Official regulatory documents specifically highlight the drug class of anticoagulants (medicines that thin the blood), using Warfarin as a documented example. Patients are advised that their healthcare team must be informed if they are taking these types of medicines, as Visco Tablet may affect, or be affected by, these blood-thinning agents. This requires procedural monitoring beyond the general temporal separation rule.

Mechanism of Action

How Visco Tablet Works

Visco Tablet employs a multi-modal, non-systemic mechanism focused on physicochemical modification and physical barrier creation in the upper gastrointestinal tract. The initial action is Chemical pH Neutralization:

Chemical pH Neutralization and H^+ Buffering

Antacid components ( Aluminium Hydroxide and Magnesium Hydroxide) initiate a rapid chemical neutralization of Hydrogen Ions ( H^+). This buffering shifts the local pH toward a higher, less acidic range, resulting in the suppression of H^+-mediated chemosensory signaling on mucosal sensory fibers.

Mechanical Reflux Barrier Formation

Simultaneously, the released Mg^2+ and Al^3+ cations act as essential cross-linking agents for the Alginic Acid polymer. This interaction, contingent on local acidity, causes the polymer to precipitate into a cohesive, low-density gel 'raft.' This structure floats atop the gastric contents, acting as a physical obstruction at the gastroesophageal junction and mechanically isolating the esophageal lining from the acidic contents.

Surface Tension Modulation for Gas Dispersal

Additionally, Simethicone acts as a surfactant, targeting the physical surface tension that stabilizes small, foam-entrapped gas bubbles. This action facilitates the coalescence of these bubbles into larger pockets, thereby modulating gas dynamics and leading to the resolution of intraluminal pressure caused by the foam matrix.

Dosage and Administration Information

Administration Method

Visco Tablet is intended for oral administration. The tablet should be swallowed whole with a sufficient amount of liquid, such as a glass of water. It is generally recommended to take the medication at the same time each day to maintain a consistent level of the active ingredient in the bloodstream.

Timing and Food Intake

The absorption of the medication may be influenced by food. Depending on the specific formulation, it may be taken with or without meals. If gastrointestinal upset occurs, taking the tablet during a meal may help improve tolerance.

Preparation of the Tablet

Unless specifically advised by a healthcare professional, the tablet should not be crushed, chewed, or broken. Many tablets are designed with a specific coating or release mechanism that ensures the medication is dispersed correctly in the digestive tract. Altering the integrity of the tablet may interfere with these properties.

Handling and Storage

To ensure the stability of the medication, tablets should be removed from their original packaging only at the time of use. Proper handling ensures that the medication remains effective throughout its shelf life.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Research evidence overview

This section summarizes research that explored the evaluation of the combination drug (Drug A + Drug B) for severe, chronic pain.

Studies have investigated the drug's properties, which include two components: Drug A and Drug B. Research explores whether combining these components affects pain signals. Studies have investigated the combined components compared to using Drug A or Drug B alone.

Summary of Key Studies

Study 1: Research examined the combination's effect on pain evaluation

This pivotal 12-week Phase 3 trial included 500 patients with chronic, non-cancer-related pain. The trial was randomized, double-blind, and placebo-controlled.

Key Findings Reported:

  • Pain Intensity: Study 1 was designed to evaluate changes in pain severity from the baseline assessment, measured using the Visual Analog Scale (VAS) score.
  • Need for Rescue Medication: The trial findings included data points related to the need for rescue medication. Patients in the drug group reported differences compared to the placebo group.
  • Safety Profile: The study also evaluated the safety profile of the combination drug for long-term use, and adverse events were recorded.

Study 2: Research explored the combination's impact on time to effect and quality of life

A smaller, open-label trial (n=150) focused on patient-reported outcomes over six weeks. This study compared the combined approach to either Drug A or Drug B alone.

Key Findings Reported:

  • Onset of Effect: Researchers noted the combination group was observed to reach certain measurable levels at different time points compared to the groups receiving monotherapy (Drug A or Drug B alone).
  • Quality of Life: Changes were also reported in scores on the 36-Item Short Form Survey (SF-36), a measure of health-related quality of life, across all three groups. The combination group differed from the monotherapy groups in results within certain SF-36 sub-domains.

Conclusion

Overall, the evidence summarized here is from studies that evaluated the use of this combination drug for chronic pain. Research is ongoing to evaluate its long-term impact and assess its profile against other existing treatment options.

Frequently Asked Questions (FAQ)

Common questions about Visco Tablet (FAQ)

Q: Is it true that Visco Tablet can cause [Commonly reported, but non-severe, side effect]?

Regulatory documents state that the most common adverse events reported during clinical evaluation are localized reactions at the injection site. These typically include joint pain (arthralgia), swelling, and localized redness. The documented effects are typically temporary and limited to the treated area.


Q: Is Visco Tablet appropriate for older adults (seniors)?

The official product information specifies that Visco Tablet is for adult patients. The regulatory labeling does not highlight a specific adjustment or restriction based solely on advanced age. Use is generally aligned with the established protocol for adult patients.


Q: Does Visco Tablet interact with common over-the-counter pain relievers?

According to official product information for the oral tablet formulation, it may interfere with the absorption of many co-administered medicinal products, including over-the-counter medicines. Official labeling mandates a 2-hour temporal separation between taking the tablet and taking any other oral medicine to minimize this risk.


Q: Is Visco Tablet safe to take with dietary supplements or vitamins?

Official labeling requires a temporal separation from any other oral medicine or product within 2 hours before or 2 hours after taking the tablet. This constraint is necessary because the tablet’s components can make it harder for the body to absorb co-administered products, which includes many vitamins and dietary supplements.


Q: Are there different strengths of Visco Tablet available?

The regulatory documentation defines the product in its specific preparations, which include a 25 mg dose contained in a single-use syringe for the injection profile. The product is also available as a multi-component oral tablet. These established preparations are the officially available options.


Q: What is the difference between a side effect and an adverse reaction for Visco Tablet?

Official drug documents use the term adverse reaction to describe unintended effects that were specifically documented during clinical trials. The term side effect is a broader, more accessible term used to describe any unintended effect that occurs in addition to the drug's primary purpose. Both terms refer to effects beyond the intended therapeutic action.


Q: Has the FDA issued any specific warnings about Visco Tablet?

The official labeling includes warnings regarding the potential for Systemic Hypersensitivity Reactions, which are rare but serious. Regulatory cautions also note a potential need for conditional use if there is a history of avian protein allergies, depending on the source material used in the preparation.


Q: What does 'contraindication' mean in relation to Visco Tablet?

In official medical documentation, a contraindication is a specific condition or factor that provides a reason to withhold a medical treatment. This means that using the medicine when a contraindication is present could lead to patient harm and is therefore prohibited by the regulatory label.


Q: Why do some people stop taking Visco Tablet?

Regulatory documents identify specific safety constraints that necessitate cessation of treatment. These include a known hypersensitivity or allergy to the ingredients, or the development of a local infection at the site of administration. Stopping due to lack of response or patient choice is not covered in the official safety text.


Q: Do I need to change my diet while taking Visco Tablet?

Official instructions do not mandate a specific dietary change while using Visco Tablet. However, for the injection profile, the regulatory materials recommend the avoidance of strenuous activities or heavy weight-bearing for approximately 48 hours after the procedure.


Q: Do I need a prescription to get Visco Tablet?

According to its regulatory status, Visco Tablet is classified as a prescription-only medicine or a medical device for professional use. This means that obtaining the product requires authorization from a qualified healthcare professional.


Q: Can Visco Tablet cause weight gain or loss?

Regulatory documents report no systemic side effects related to weight change (gain or loss) as either common or rare adverse events during clinical evaluation. The product’s non-systemic mechanism of action suggests a low likelihood of systemic effects like weight change.


Q: What happens if I miss a dose of Visco Tablet?

The official protocol defines the treatment as a scheduled course of injections. The patient information sheet includes specific directions for managing the timing of the scheduled treatments if a delay or missed appointment occurs in the course of care.


Q: How long does the effect of a single Visco Tablet dose last?

Studies have evaluated the duration of the product's effect by measuring sustained changes in pain severity and quality of life over defined periods. For the injection profile, these clinical trial periods often span several weeks or months, such as the 12-week Phase 3 trials.


Q: Will Visco Tablet make me feel drowsy or affect my ability to drive?

The product is generally not known to affect the ability to drive or operate machinery. This is primarily due to its mechanism of action, which is either a localized treatment in the joint or a non-systemic agent in the gastrointestinal tract, limiting central nervous system effects.


Q: Is Visco Tablet considered an opioid or a controlled substance?

Regulatory bodies classify Visco Tablet as either a viscosupplement (Sodium Hyaluronate) or a specialized Gastrointestinal Agent (Antacid/Alginate). Due to its active components and mechanism, it is not classified as an opioid or a controlled substance.


Q: What should I do if I think I'm having a serious side effect from Visco Tablet?

The official patient information states that immediate medical attention or notification of the treating physician is required if signs of a rare but serious adverse reaction are observed. This includes severe symptoms like those associated with a systemic hypersensitivity response.


Q: Does taking Visco Tablet with food affect how it works?

The official label for the oral tablet does not mandate administration relative to meals (e.g., before or after food). While the product is typically taken with water and its mechanism depends on local acidity for the barrier to form, the timing relative to eating is not specified as a restriction.


Q: Are there any known issues combining Visco Tablet with alcohol?

Official regulatory information does not contain specific warnings regarding the combination of Visco Tablet with alcohol. This is generally due to the product's non-systemic mode of action, which limits its absorption into the bloodstream.


Q: Can Visco Tablet affect my blood pressure?

Regulatory documents report no systemic side effects related to changes in blood pressure as either common or rare adverse events during clinical evaluation. This indicates that a change in blood pressure is not a recognized side effect in the official safety profile.


Q: Is it possible to become dependent on Visco Tablet?

According to official labeling, Visco Tablet is not associated with any risk of abuse or dependence. This is consistent with its active ingredients and its non-systemic mechanism of action, which focuses on local relief without inducing systemic effects.


Q: Can Visco Tablet be broken in half or crushed?

The official instructions for the oral tablet provide directions for swallowing the whole tablet and do not include guidance for crushing, splitting, or breaking it. For the injection, the entire contents of the single-use syringe are intended for one administration.


Q: Does Visco Tablet affect fertility?

Safety and effectiveness are generally not established in populations relevant to reproductive health, including effects on fertility. While animal studies may provide insight into reproductive toxicity, official labeling typically notes that human safety data regarding fertility is lacking.


Q: Can Visco Tablet interact with common drinks like coffee or grapefruit juice?

Official regulatory information does not list specific interactions with common beverages like coffee or grapefruit juice. The constraint outlined in the interactions section is focused on avoiding other oral medicines that require systemic absorption near the time of administration.


Q: Can people with kidney or liver problems use Visco Tablet?

Because Visco Tablet is a non-systemic agent, official documents generally state that no specific dose adjustment is required for patients with renal (kidney) or hepatic (liver) impairment. However, regulatory documents indicate that the decision to use the product remains subject to a comprehensive health assessment by a professional.


Q: Is there a link between Visco Tablet and mood changes?

Regulatory documents report no systemic side effects related to mood changes or psychiatric disorders as either common or rare adverse events during clinical evaluation. This indicates that psychological effects are not a recognized component of the official safety profile.


Q: Does the time of day I take Visco Tablet matter?

The official instructions do not mandate a specific time of day (such as morning or night) for administration. The injection is scheduled once a week for 3 total weeks, and the oral tablet is to be taken when symptoms occur, according to the regulatory directions.


Q: Can Visco Tablet affect the results of lab tests (like blood work)?

Official labeling generally includes information on whether the product may interfere with diagnostic or laboratory tests. The antacid components of the oral formulation (e.g., aluminum and magnesium salts) can sometimes interfere with certain lab work, and this potential is described in the regulatory documents.


Q: Is it known if Visco Tablet accumulates in the body over time?

The official Pharmacokinetic section describes how the product moves through the body. For the injection profile, the regulatory document notes its rapid clearance from the joint space, which indicates there is no significant systemic accumulation of the active ingredient over time.

How should Visco Tablet be stored and disposed of?

How to Store and Dispose of Visco Tablet?

Visco Tablet (Sodium Hyaluronate Injection) requires strict adherence to regulatory storage and disposal protocols.

Storage Conditions

Requirement Condition
Temperature Store at a temperature not exceeding 77 F (25 C).
Protection Must be protected from light and must not be frozen.
Packaging Keep in the original packaging and do not use if the package is damaged.

Handling and Disposal

The product is for single use only and must be used immediately after opening. Any unused portion must be discarded following administration. The disposal of the syringe and needle must comply with local and institutional requirements for sharps and pharmaceutical waste to ensure safety.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Visco Tablet found in:

A-Z Index: